Details of the Drug

General Information of Drug (ID: DMQB3HD)

Drug Name
XmAb22841
Synonyms XmAb841
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0BOM7

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Not Available [2]
Lymphocyte activation gene 3 protein (LAG3) TTNVXAW LAG3_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 2.73E-01 0.02 0.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03849469) A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Xencor.